Epstein-barr virus-associated lymphomas

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 372, Issue 1732, 2017, Pages

  Shannon Lowe, Claire ^a   Rickinson, Alan B ^a   Bell, Andrew I ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Burkitt lymphoma; Diffuse large B cell lymphoma; Epstein barr virus; Hodgkin lymphoma; Post transplant lymphoproliferative disease; T NK lymphoma

Indexed keywords

CELLS AND CELL COMPONENTS; GENE EXPRESSION; GROWTH; HOST; IMMUNE SYSTEM; TUMOR; VIRUS;

HUMAN HERPESVIRUS 4;

CARCINOGENESIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOMA; PHYSIOLOGY; VIROLOGY;

CARCINOGENESIS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; LYMPHOMA;

EID: 85029380404     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2016.0271     Document Type: Review

References (152)

1. Young LS, Yap LF, Murray PG. 2016 Epstein-Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789-802. (doi:10. 1038/nrc.2016.92)
2. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro, M. 2013 The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3, 227-232. (doi:10.1016/j.coviro.2013.04.005)
3. Hislop AD, Taylor GS, Sauce, D, Rickinson AB. 2007 Cellular responses to viral infection in humans:lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25, 587-617. (doi:10.1146/annurev. immunol.25.022106.141553)
4. Hislop AD et al. 2005 Tonsillar homing of Epstein-Barr virus-specific CD8þ T cells and the virus-host balance. J. Clin. Invest. 115, 2546-2555. (doi:10. 1172/JCI24810)
5. Woon HG et al. 2016 Compartmentalization of total and virus-specific tissue-resident memory CD8þ T cells in human lymphoid organs. PLoS Pathog. 12, e1005799. (doi:10.1371/journal.ppat.1005799)
6. Gottschalk S, Rooney CM, Heslop HE. 2005 Posttransplant lymphoproliferative disorders. Annu. Rev. Med. 56, 29-44. (doi:10.1146/annurev.med.56. 082103.104727)
7. Basso, K, Dalla-Favera, R. 2015 Germinal centres and B cell lymphomagenesis. Nat. Rev. Immunol. 15, 172-184. (doi:10.1038/nri3814)
8. Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger, F, Delecluse HJ. 2003 Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease:similarities to EBV-positive Hodgkin’s lymphoma. Lancet 361, 217-223. (doi:10.1016/S0140-6736(03)12271-4)
9. Morscio J, Finalet Ferreiro J, Vander Borght S, Bittoun E, Gheysens O, Dierickx D, Verhoef G, Wlodarska, I, Tousseyn, T. 2017 Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. Mod. Pathol. 30, 370-381. (doi:10.1038/ modpathol.2016.199)
10. Swerdlow SH et al. 2016 The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375-2390. (doi:10.1182/ blood-2016-01-643569)
11. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. 2012 Burkitt’s lymphoma. Lancet 379, 1234-1244. (doi:10.1016/S0140-6736(11)61177-X)
12. Moormann AM, Bailey JA. 2016 Malaria-how this parasitic infection aids and abets EBV-associated Burkitt lymphomagenesis. Curr. Opin. Virol. 20, 78-84. (doi:10.1016/j.coviro.2016.09.006)
13. Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, Harrington Jr WJ, Bacchi CE. 2008 Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am. J. Clin. Pathol. 130, 946-956. (doi:10.1309/ AJCP64YOHAWLUMPK)
14. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM. 2010 AIDSrelated Burkitt lymphoma in the United States:what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 116, 5600-5604. (doi:10.1182/blood-2010-03-275917)
15. Clifford GM et al. 2005 Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst. 97, 425-432. (doi:10.1093/jnci/ dji072)
16. Carroll V, Garzino-Demo A. 2015 HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog. Dis. 73, 44. (doi:10.1093/femspd/ftv044)
17. Arvey A et al. 2015 The tumor virus landscape of AIDS-related lymphomas. Blood 125, e14-e22. (doi:10.1182/blood-2014-11-599951)
18. Hummel M et al. 2006 A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354, 2419-2430. (doi:10.1056/NEJMoa055351)
19. Dave SS et al. 2006 Molecular diagnosis of Burkitt’s lymphoma. N. Engl. J. Med. 354, 2431-2442. (doi:10.1056/NEJMoa055759)
20. Guikema JE, Schuuring E, Kluin PM. 2008 Structure and consequences of IGH switch breakpoints in Burkitt lymphoma. J. Natl Cancer Inst. Monogr. 2008, 32-36. (doi:10.1093/jncimonographs/ lgn020)
21. Allday MJ. 2009 How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? Semin. Cancer Biol. 19, 366-376. (doi:10.1016/j.semcancer.2009.07.007)
22. Scheller H, Tobollik S, Kutzera A, Eder M, Unterlehberg J, Pfeil I, Jungnickel B. 2010 c-Myc overexpression promotes a germinal center-like program in Burkitt’s lymphoma. Oncogene 29, 888-897. (doi:10.1038/onc.2009.377)
23. Lindstrom MS, Wiman KG. 2002 Role of genetic and epigenetic changes in Burkitt lymphoma. Semin. Cancer Biol. 12, 381-387. (doi:10.1016/S1044-579X(02)00058-5)
24. Schmitz R et al. 2012 Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120. (doi:10.1038/nature11378)
25. Love C et al. 2012 The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44, 1321-1325. (doi:10.1038/ng.2468)
26. Richter J et al. 2012 Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44, 1316-1320. (doi:10. 1038/ng.2469)
27. Abate F et al. 2015 Distinct viral and mutational spectrum of endemic Burkitt lymphoma. PLoS Pathog. 11, e1005158. (doi:10.1371/journal.ppat. 1005158)
28. Giulino-Roth L et al. 2012 Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120, 5181-5184. (doi:10.1182/blood-2012-06-437624)
29. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. 2014 Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb. Perspect. Med. 4, a014282. (doi:10.1101/cshperspect.a014282)
30. Sander S et al. 2012 Synergy between PI3 K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22, 167-179. (doi:10.1016/j.ccr.2012. 06.012)
31. Thorley-Lawson DA, Allday MJ. 2008 The curious case of the tumour virus: 50 years of Burkitt’s lymphoma. Nat. Rev. Microbiol. 6, 913-924. (doi:10.1038/nrmicro2015)
32. Rowe M, Fitzsimmons L, Bell AI. 2014 Epstein-Barr virus and Burkitt lymphoma. Chin. J. Cancer 33, 609-619. (doi:10.5732/cjc.014.10190)
33. Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M. 2015 Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology 474, 117-130. (doi:10.1016/j. virol.2014.10.030)
34. Komano J, Sugiura M, Takada K. 1998 Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt’s lymphoma cell line Akata. J. Virol. 72, 9150-9156.
35. Nanbo A, Takada K. 2002 The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev. Med. Virol. 12, 321-326. (doi:10.1002/rmv. 363)
36. Tempera I et al. 2015 Identification of MEF2B, EBF1, and IL6R as direct gene targets of Epstein-Barr virus (EBV) nuclear antigen 1 critical for EBV-infected B-lymphocyte survival. J. Virol. 90, 345-355. (doi:10.1128/JVI.02318-15)
37. Lu J, Murakami M, Verma SC, Cai Q, Haldar S, Kaul R, Wasik MA, Middeldorp J, Robertson ES. 2011 Epstein-Barr virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBVpositive B-lymphoma cells through up-regulation of survivin. Virology 410, 64-75. (doi:10.1016/j. virol.2010.10.029)
38. Dheekollu J, Malecka K, Wiedmer A, Delecluse HJ, Chiang AK, Altieri DC, Messick TE, Lieberman PM. 2017 Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr virus episomal latency. Oncotarget 8, 7248-7264. (doi:10.18632/oncotarget.14540)
39. Frappier L. 2012 Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses 4, 1537-1547. (doi:10.3390/ v4091537)
40. Klinke O, Feederle R, Delecluse HJ. 2014 Genetics of Epstein-Barr virus microRNAs. Semin. Cancer Biol. 26, 52-59. (doi:10.1016/j.semcancer.2014.02.002)
41. Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, Hammerschmidt W, Sugden B. 2014 Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 33, 1258-1264. (doi:10.1038/ onc.2013.71)
42. Piccaluga PP et al. 2016 Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget 7, 224-240. (doi:10.18632/oncotarget.4399)
43. Ambrosio MR et al. 2014 The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma. Infect. Agent. Cancer 9, 12. (doi:10.1186/1750-9378-9-12)
44. Harold C, Cox D, Riley KJ. 2016 Epstein-Barr viral microRNAs target caspase 3. Virol. J. 13, 145. (doi:10.1186/s12985-016-0602-7)
45. Robbiani DF et al. 2008 AID is required for the chromosomal breaks in c-myc that lead to c-myc/ IgH translocations. Cell 135, 1028-1038. (doi:10. 1016/j.cell.2008.09.062)
46. Epeldegui M, Hung YP, McQuay A, Ambinder RF, Martinez-Maza O. 2007 Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol. Immunol. 44, 934-942. (doi:10.1016/j.molimm.2006.03.018)
47. Kalchschmidt JS, Bashford-Rogers R, Paschos K, Gillman AC, Styles CT, Kellam P, Allday MJ. 2016 Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J. Exp. Med. 213, 921-928. (doi:10.1084/ jem.20160120)
48. Wood CD et al. 2016 MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife 5, e18270. (doi:10.7554/eLife.18270)
49. Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, Thorley-Lawson DA. 2014 A multifactorial role for P. falciparum malaria in endemic Burkitt’s lymphoma pathogenesis. PLoS Pathog. 10, e1004170. (doi:10. 1371/journal.ppat.1004170)
50. Robbiani DF et al. 2015 Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma. Cell 162, 727-737. (doi:10.1016/j. cell.2015.07.019)
51. Rickinson AB. 2014 Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin. Cancer Biol. 26, 99-115. (doi:10.1016/j. semcancer.2014.04.004)
52. Magrath I. 2012 Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br. J. Haematol. 156, 744-756. (doi:10.1111/j.1365-2141.2011. 09013.x)
53. Amato T et al. 2016 Clonality analysis of immunoglobulin gene rearrangement by nextgeneration sequencing in endemic Burkitt lymphoma suggests antigen drive activation of BCR as opposed to sporadic Burkitt lymphoma. Am. J. Clin. Pathol. 145, 116-127. (doi:10.1093/ ajcp/aqv011)
54. Piccaluga PP et al. 2011 Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 117, 3596-3608. (doi:10.1182/blood-2010-08-301556)
55. Kaymaz Y, Oduor CI, Yu H, Otieno JA, Ong’echa JM, Moormann AM, Bailey JA. 2017 Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences. Mol. Cancer Res. 15, 499. (doi:10.1158/ 1541-7786.MCR-16-0305)
56. Pileri SA et al. 2002 Hodgkin’s lymphoma: the pathologist’s viewpoint. J. Clin. Pathol. 55, 162-176. (doi:10.1136/jcp.55.3.162)
57. Mathas S, Hartmann S, Kuppers R. 2016 Hodgkin lymphoma: pathology and biology. Semin. Hematol. 53, 139-147. (doi:10.1053/j.seminhematol.2016. 05.007)
58. Aldinucci D, Celegato M, Casagrande N. 2016 Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 380, 243-252. (doi:10.1016/j.canlet.2015.10. 007)
59. Glaser SL et al. 1997 Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int. J. Cancer 70, 375-382. (doi:10.1002/(SICI)1097-0215(19970207)70:4,375::AID-IJC1.3.0.CO;2-T)
60. Cesarman E. 2013 Pathology of lymphoma in HIV. Curr. Opin. Oncol. 25, 487-494. (doi:10.1097/01. cco.0000432525.70099.a4)
61. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer, R, Hansmann ML. 1994 Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc. Natl Acad. Sci. USA 91, 10962-10966. (doi:10.1073/pnas.91.23.10962)
62. Schwering I et al. 2003 Loss of the B-lineagespecific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101, 1505-1512. (doi:10.1182/blood-2002-03-0839)
63. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. 2002 Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21, 4908-4920. (doi:10.1038/sj.onc. 1205629)
64. Guan H, Xie L, Wirth T, Ushmorov A. 2016 Repression of TCF3/E2A contributes to Hodgkin lymphomagenesis. Oncotarget 7, 36 854-36 864. (doi:10.18632/oncotarget.9210)
65. Cozen W et al. 2014 A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat. Commun. 5, 3856. (doi:10. 1038/ncomms4856)
66. Farrell K, Jarrett RF. 2011 The molecular pathogenesis of Hodgkin lymphoma. Histopathology 58, 15-25. (doi:10.1111/j.1365-2559.2010.03705.x)
67. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. 1996 Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med. 184, 1495-1505. (doi:10.1084/jem.184.4.1495)
68. Weniger MA, Kuppers R. 2016 NF-kB deregulation in Hodgkin lymphoma. Semin. Cancer Biol. 39, 32-39. (doi:10.1016/j.semcancer.2016.05.001)
69. Joos S et al. 2000 Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30þ Hodgkin cells. Cancer Res. 60, 549-552.
70. Reichel J et al. 2015 Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 125, 1061-1072. (doi:10.1182/blood-2014-11-610436)
71. Liu Y et al. 2014 The mutational landscape of Hodgkin lymphoma cell lines determined by wholeexome sequencing. Leukemia 28, 2248-2251. (doi:10.1038/leu.2014.201)
72. Roemer MG et al. 2016 Classical Hodgkin lymphoma with reduced beta2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol. Res. 4, 910-916. (doi:10.1158/2326-6066.CIR-16-0201)
73. Vockerodt M et al. 2008 The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin’s Reed-Sternberg-like phenotype. J. Pathol. 216, 83-92. (doi:10.1002/path.2384)
74. Vrzalikova K et al. 2011 Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 117, 5907-5917. (doi:10.1182/ blood-2010-09-307710)
75. Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG. 2013 Suppression of the LMP2A target gene, EGR-1, protects Hodgkin’s lymphoma cells from entry to the EBV lytic cycle. J. Pathol. 230, 399-409. (doi:10.1002/path.4198)
76. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. 2006 Molecular biology of Hodgkin’s and Reed/Sternberg cells in Hodgkin’s lymphoma. Int. J. Cancer 118, 1853-1861. (doi:10. 1002/ijc.21716)
77. Chaganti S, Bell AI, Pastor NB, Milner AE, Drayson M, Gordon J, Rickinson AB. 2005 Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 106, 4249-4252. (doi:10.1182/blood-2005-06-2327)
78. Schmitz R et al. 2009 TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 206, 981-989. (doi:10.1084/jem.20090528)
79. Renne C et al. 2007 The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin’s lymphoma. Int. J. Cancer 120, 2504-2509. (doi:10. 1002/ijc.22511)
80. Leonard S, Wei W, Anderton J, Vockerodt M, Rowe M, Murray PG, Woodman CB. 2011 Epigenetic and transcriptional changes which follow Epstein-Barr virus infection of germinal center B cells and their relevance to the pathogenesis of Hodgkin’s lymphoma. J. Virol. 85, 9568-9577. (doi:10.1128/ JVI.00468-11)
81. Alizadeh AA et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511. (doi:10. 1038/35000501)
82. Oyama T et al. 2003 Senile EBVþ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am. J. Surg. Pathol. 27, 16-26. (doi:10.1097/00000478-200301000-00003)
83. Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S. 2008 Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci. 99, 1085-1091. (doi:10.1111/j. 1349-7006.2008.00813.x)
84. Cohen M, De Matteo E, Narbaitz M, Carreno FA, Preciado MV, Chabay PA. 2013 Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns:analysis of viral role in tumor microenvironment. Int. J. Cancer 132, 1572-1580. (doi:10.1002/ijc. 27845)
85. Cohen M, Narbaitz M, Metrebian F, De Matteo E, Preciado MV, Chabay PA. 2014 Epstein-Barr viruspositive diffuse large B-cell lymphoma association is not only restricted to elderly patients. Int. J. Cancer 135, 2816-2824. (doi:10.1002/ijc.28942)
86. Cardenas D et al. 2015 Epstein-Barr virus-specific CD8þ T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired. Clin. Exp. Immunol. 182, 173-183. (doi:10.1111/cei. 12682)
87. Ok CY, Papathomas TG, Medeiros LJ, Young KH. 2013 EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 122, 328-340. (doi:10.1182/ blood-2013-03-489708)
88. White RE et al. 2012 EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 122, 1487-1502. (doi:10.1172/JCI58092)
89. Sebastian E et al. 2016 High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. Ann. Hematol. 95, 253-262. (doi:10.1007/s00277-015-2552-3)
90. Shaffer 3rd AL, Young RM, Staudt LM. 2012 Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30, 565-610. (doi:10.1146/annurevimmunol-020711-075027)
91. Mandelbaum J et al. 2010 BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18, 568-579. (doi:10.1016/j.ccr.2010.10.030)
92. Pasqualucci L et al. 2006 Inactivation of the PRDM1/ BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311-317. (doi:10.1084/jem. 20052204)
93. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. 2006 Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large Bcell lymphomas. Blood 107, 4090-4100. (doi:10. 1182/blood-2005-09-3778)
94. Lam LT et al. 2005 Small molecule inhibitors of IkB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 11, 28-40.
95. Kato H et al. 2014 Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Cancer Sci. 105, 537-544. (doi:10.1111/cas.12389)
96. Loong F et al. 2010 Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod. Pathol. 23, 493-501. (doi:10.1038/modpathol. 2009.168)
97. Sanchez-Gonzalez B, Garcia M, Montserrat F, Sanchez M, Angona A, Solano A, Salar A. 2013 Diffuse large B-cell lymphoma associated with chronic inflammation in metallic implant. J. Clin. Oncol. 31, e148-e151. (doi:10.1200/JCO.2012.42. 8250)
98. Cheuk W, Chan AC, Chan JK, Lau GT, Chan VN, Yiu HH. 2005 Metallic implant-associated lymphoma: a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma? Am. J. Surg. Pathol. 29, 832-836. (doi:10.1097/01.pas. 0000157747.10967.f4)
99. Copie-Bergman C, Niedobitek G, Mangham DC, Selves J, Baloch K, Diss TC, Knowles DN, Delsol G, Isaacson PG. 1997 Epstein-Barr virus in B-cell lymphomas associated with chronic suppurative inflammation. J. Pathol. 183, 287-292. (doi:10. 1002/(SICI)1096-9896(199711)183:3,287::AIDPATH932.3.0. CO;2-Q)
100. Kanno H, Naka N, Yasunaga Y, Iuchi K, Yamauchi S, Hashimoto M, Aozasa K. 1997 Production of the immunosuppressive cytokine interleukin-10 by Epstein-Barr-virus-expressing pyothorax-associated lymphoma: possible role in the development of overt lymphoma in immunocompetent hosts. Am. J. Pathol. 150, 349-357.
101. Kanno H, Naka N, Yasunaga Y, Aozasa K. 1997 Role of an immunosuppressive cytokine, interleukin-10, in the development of pyothorax-associated lymphoma. Leukemia 11(Suppl. 3), 525-526.
102. Kanno H, Yasunaga Y, Iuchi K, Yamauchi S, Tatekawa T, Sugiyama H, Aozasa K. 1996 Interleukin-6-mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma. Lab. Invest. 75, 167-173.
103. Kanno H, Ohsawa M, Hashimoto M, Iuchi K, Nakajima Y, Aozasa K. 1999 HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigenpositive lymphomas. Int. J. Cancer 82, 630-634. (doi:10.1002/(SICI)1097-0215(19990827)82:5,630::AID-IJC2.3.0.CO;2-D)
104. Kanno H, Nakatsuka S, Iuchi K, Aozasa K. 2000 Sequences of cytotoxic T-lymphocyte epitopes in the Epstein-Barr virus (EBV) nuclear antigen-3B gene in a Japanese population with or without EBV-positive lymphoid malignancies. Int. J. Cancer 88, 626-632. (doi:10.1002/1097-0215(20001115)88:4,626::AID-IJC17.3.0.CO;2-Q)
105. Nishiu M et al. 2004 Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci. 95, 828-834. (doi:10. 1111/j.1349-7006.2004.tb02189.x)
106. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. 2014 Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 28, 2313-2318. (doi:10.1097/QAD.0000000000000428)
107. Glotz D et al. 2012 The Seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation 94, 784-793. (doi:10. 1097/TP.0b013e318269e64f)
108. Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. 2016 Posttransplant lymphoproliferative disorders. Nat. Rev. Dis. Primers 2, 15088. (doi:10.1038/nrdp. 2015.88)
109. Ferreiro JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I. 2016 EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am. J. Transplant. 16, 414-425. (doi:10.1111/ajt. 13558)
110. Morscio J et al. 2013 Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am. J. Transplant. 13, 1305-1316. (doi:10.1111/ajt.12196)
111. Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, Naresh KN. 2017 Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br. J. Haematol. 178, 341-491. (doi:10.1111/bjh.14633)
112. Craig FE, Johnson LR, Harvey SA, Nalesnik MA, Luo JH, Bhattacharya SD, Swerdlow SH. 2007 Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn. Mol. Pathol. 16, 158-168. (doi:10.1097/PDM. 0b013e31804f54a9)
113. Delecluse HJ et al. 1997 Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89, 1413-1420.
114. Nador RG, Cesarman E, Knowles DM, Said JW. 1995 Herpes-like DNA sequences in a body-cavity-based lymphoma in an HIV-negative patient. N. Engl. J. Med. 333, 943. (doi:10.1056/ NEJM199510053331417)
115. Dolcetti R, Gloghini A, Caruso A, Carbone A. 2016 A lymphomagenic role for HIV beyond immune suppression? Blood 127, 1403-1409. (doi:10.1182/ blood-2015-11-681411)
116. Schulz TF, Cesarman E. 2015 Kaposi sarcomaassociated herpesvirus: mechanisms of oncogenesis. Curr. Opin. Virol. 14, 116-128. (doi:10.1016/j. coviro.2015.08.016)
117. Fan W, Bubman D, Chadburn A, Harrington Jr WJ, Cesarman E, Knowles DM. 2005 Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J. Virol. 79, 1244-1251. (doi:10.1128/ JVI.79.2.1244-1251.2005)
118. Kimura H et al. 2003 Prognostic factors for chronic active Epstein-Barr virus infection. J. Infect. Dis. 187, 527-533. (doi:10.1086/367988)
119. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, Morishima T. 2001 Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98, 280-286. (doi:10.1182/ blood.V98.2.280)
120. Kimura H et al. 2005 Differences between T celltype and natural killer cell-type chronic active Epstein-Barr virus infection. J. Infect. Dis. 191, 531-539. (doi:10.1086/427239)
121. Ohga S et al. 1999 Restricted diversification of Tcells in chronic active Epstein-Barr virus infection:potential inclination to T-lymphoproliferative disease. Am. J. Hematol. 61, 26-33. (doi:10.1002/ (SICI)1096-8652(199905)61:1,26::AID-AJH6.3.0. CO;2-R)
122. Oyoshi MK et al. 2003 Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection. Am. J. Pathol. 162, 1629-1638. (doi:10.1016/ S0002-9440(10)64297-6)
123. Fujieda M, Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. 1993 Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr. Jpn 35, 394-399. (doi:10.1111/j.1442-200X.1993.tb03079.x)
124. Sugaya N, Kimura H, Hara S, Hoshino Y, Kojima S, Morishima T, Tsurumi T, Kuzushima K. 2004 Quantitative analysis of Epstein-Barr virus (EBV)- specific CD8þ T cells in patients with chronic active EBV infection. J. Infect. Dis. 190, 985-988. (doi:10. 1086/423285)
125. Joncas J, Monczak Y, Ghibu F, Alfieri C, Bonin A, Ahronheim G, Rivard G. 1989 Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J. Med. Virol. 28, 110-117. (doi:10. 1002/jmv.1890280211)
126. Fox CP et al. 2010 A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116, 3695-3704. (doi:10.1182/blood-2010-06-292268)
127. Wakiguchi H, Fujieda M, Matsumoto K, Ohara Y, Wakiguchi A, Kurashige T. 1988 Defective killer cell activity in patients with chronic active Epstein-Barr virus infection. Acta Med. Okayama 42, 137-142.
128. Ohga S et al. 2004 Dominant expression of interleukin-10 and transforming growth factor-beta genes in activated T-cells of chronic active Epstein-Barr virus infection. J. Med. Virol. 74, 449-458. (doi:10.1002/jmv.20197)
129. Cohen JI et al. 2011 Characterization and treatment of chronic active Epstein-Barr virus disease: a 28- year experience in the United States. Blood 117, 5835-5849. (doi:10.1182/blood-2010-11-316745)
130. Cohen JI. 2015 Primary immunodeficiencies associated with EBV disease. Curr. Top. Microbiol. Immunol. 390, 241-265. (doi:10.1007/978-3-319-22822-8_10)
131. Tangye SG, Palendira U, Edwards ES. 2017 Human immunity against EBV-lessons from the clinic. J. Exp. Med. 214, 269-283. (doi:10.1084/jem. 20161846)
132. Au WY. 2010 Current management of nasal NK/T-cell lymphoma. Oncology 24, 352-358.
133. Pagano L et al. 2006 NK/T-cell lymphomas ʼnasal type’: an Italian multicentric retrospective survey. Ann. Oncol. 17, 794-800. (doi:10.1093/annonc/ mdl015)
134. Au WY et al. 2005 Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann. Oncol. 16, 206-214. (doi:10.1093/annonc/mdi037)
135. Chauchet A et al. 2012 Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J. Hematol. Oncol. 5, 27. (doi:10.1186/1756-8722-5-27)
136. Suzuki R et al. 2010 Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann. Oncol. 21, 1032-1040. (doi:10.1093/ annonc/mdp418)
137. Lee J et al. 2006 Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 24, 612-618. (doi:10.1200/JCO.2005.04.1384)
138. Drenou B et al. 1997 CD32 CD56þ non-Hodgkin’s lymphomas with an aggressive behavior related to multidrug resistance. Blood 89, 2966-2974.
139. Nakashima Y et al. 2005 Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 44, 247-255. (doi:10. 1002/gcc.20245)
140. Jiang L et al. 2015 Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat. Genet. 47, 1061-1066. (doi:10. 1038/ng.3358)
141. Huang Y, de Leval L, Gaulard P. 2013 Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract. Res. Clin. Haematol. 26, 57-74. (doi:10. 1016/j.beha.2013.04.006)
142. Quintanilla-Martinez L et al. 2001 p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am. J. Pathol. 159, 2095-2105. (doi:10.1016/ S0002-9440(10)63061-1)
143. Kucuk C et al. 2015 Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat. Commun. 6, 6025. (doi:10.1038/ncomms7025)
144. Koo GC et al. 2012 Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2, 591-597. (doi:10. 1158/2159-8290.CD-12-0028)
145. Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, Su IJ. 2005 Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 106, 3090-3096. (doi:10.1182/blood-2005-04-1406)
146. Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O’Connor N, Rowe M. 2010 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin. Infect. Dis. 51, 66-69. (doi:10.1086/653424)
147. Pajic A et al. 2001 Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int. J. Cancer 93, 810-816. (doi:10. 1002/ijc.1404)
148. Polack A et al. 1996 c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl Acad. Sci. USA 93, 10 411-10 416. (doi:10.1073/pnas.93.19. 10411)
149. Cancer Genome Atlas Research Network. 2014 Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202-209. (doi:10. 1038/nature13480)
150. Tsai CL et al. 2006 Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 66, 11 668-11 676. (doi:10.1158/0008-5472.CAN-06-2194)
151. Hino R et al. 2009 Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 69, 2766-2774. (doi:10.1158/0008-5472.CAN-08-3070)
152. Queen KJ, Shi M, Zhang F, Cvek U, Scott RS. 2013 Epstein-Barr virus-induced epigenetic alterations following transient infection. Int. J. Cancer 132, 2076-2086. (doi:10.1002/ijc.27893)